{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+Placebo-controlled+antidepressant+treatment&page=4",
    "query": {
      "intervention": "Placebo Comparator: Placebo-controlled antidepressant treatment",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 231,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+Placebo-controlled+antidepressant+treatment&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+Placebo-controlled+antidepressant+treatment&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T04:23:54.647Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00086190",
      "title": "Study of Antidepressants in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease",
        "Depression"
      ],
      "interventions": [
        {
          "name": "paroxetine",
          "type": "DRUG"
        },
        {
          "name": "venlafaxine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2005-06",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2013-01-04",
      "last_synced_at": "2026-10-12T04:23:54.647Z",
      "location_count": 15,
      "location_summary": "San Francisco, California • Gainesville, Florida • Miami, Florida + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00086190"
    },
    {
      "nct_id": "NCT00167310",
      "title": "Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Major Depression",
        "Bipolar Disorder",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Eicosapentaenoic acid (omega-3 fatty acid)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2005-09",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-04-10",
      "last_synced_at": "2026-10-12T04:23:54.647Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00167310"
    },
    {
      "nct_id": "NCT04276259",
      "title": "Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo",
          "type": "DRUG"
        },
        {
          "name": "IM Placebo",
          "type": "DRUG"
        },
        {
          "name": "Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Marta Peciña, MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2020-10-19",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-12T04:23:54.647Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04276259"
    },
    {
      "nct_id": "NCT02484456",
      "title": "Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depression"
      ],
      "interventions": [
        {
          "name": "AV 101 (4-Chlorokynurenine)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2015-10-14",
      "completion_date": "2019-12-03",
      "has_results": true,
      "last_update_posted_date": "2022-04-11",
      "last_synced_at": "2026-10-12T04:23:54.647Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02484456"
    },
    {
      "nct_id": "NCT01912196",
      "title": "Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder (MDD)"
      ],
      "interventions": [
        {
          "name": "MSI-195",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MSI Methylation Sciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 376,
      "start_date": "2013-10",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2016-03-18",
      "last_synced_at": "2026-10-12T04:23:54.647Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Encino, California • Escondido, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01912196"
    },
    {
      "nct_id": "NCT02674529",
      "title": "Study of Neural Responses Induced by Antidepressant Effects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Escitalopram",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Real-time Neurofeedback fMRI task pre- and post-RCT",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Marta Peciña, MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2016-09",
      "completion_date": "2021-05",
      "has_results": true,
      "last_update_posted_date": "2022-11-03",
      "last_synced_at": "2026-10-12T04:23:54.647Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02674529"
    },
    {
      "nct_id": "NCT06011577",
      "title": "Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Depression"
      ],
      "interventions": [
        {
          "name": "REL-1017",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Levomecor Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2023-08-17",
      "completion_date": "2024-12-19",
      "has_results": true,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-12T04:23:54.647Z",
      "location_count": 36,
      "location_summary": "Dothan, Alabama • Homewood, Alabama • Anaheim, California + 32 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06011577"
    },
    {
      "nct_id": "NCT05449444",
      "title": "Masitinib for the Treatment of Severe Mast Cell Activation Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mast Cell Activation Syndrome"
      ],
      "interventions": [
        {
          "name": "Masitinib 4.5 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Best supportive care",
          "type": "OTHER"
        },
        {
          "name": "Masitinib 6.0 mg/kg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AB Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 72,
      "start_date": "2022-07-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-02-06",
      "last_synced_at": "2026-10-12T04:23:54.647Z",
      "location_count": 1,
      "location_summary": "Weldon Spring, Missouri",
      "locations": [
        {
          "city": "Weldon Spring",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05449444"
    },
    {
      "nct_id": "NCT00101452",
      "title": "Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "S-adenosyl-l-methionine",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maurizio Fava, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 199,
      "start_date": "2005-04",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-10-12T04:23:54.647Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Providence, Rhode Island",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101452"
    },
    {
      "nct_id": "NCT02196506",
      "title": "Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder",
        "Depression",
        "Depressive Disorder, Major",
        "Mood Disorders",
        "Mental Disorders"
      ],
      "interventions": [
        {
          "name": "Placebo + ADT",
          "type": "DRUG"
        },
        {
          "name": "Brexpiprazole +ADT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 837,
      "start_date": "2014-07",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-10-12T04:23:54.647Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Denver, Colorado + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02196506"
    }
  ]
}